An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

1. Successful engraftment of AGT103-T with at least 30 days post-infusion safety monitoring during the AGT-HC-168 Parent Study.

Note: Successful engraftment is defined as detectable levels of AGT103-T cells bearing the AGT103 lentivirus vector.

2. HIV \<50 copies of viral RNA/mL plasma on stable ART.

3. Continuation on the same ART regimen during the AGT-HC-168 Parent Study unless change in treatment with ART regimen is medically indicated.

4. CD4 T cell count \>400 cells/mm3.

5. Ability to understand the study and willingness to comply with study-required procedures and visits.

6. Written informed consent signed and dated by the study participant.

7. A negative pregnancy test for females of childbearing potential. A female participant is considered to be of childbearing potential if she is menstruating, has an intact uterus and at least 1 ovary, and is less than 2 years postmenopausal.

8. Unless medically prescribed, a negative drug test for amphetamines; barbiturates; benzodiazepines; cocaine; methadone (Dolophine®); opiates (codeine, morphine only); phencyclidine (PCP); propoxyphene.

9. Female participants of childbearing potential and male participants who are sexually active with a partner of childbearing potential must agree to use an adequate method of contraception at screening and throughout trial participation.

10. Female and male participants who are sexually active with a partner must agree to abstain from sexual activity or use an adequate method of protection (e.g., condoms) at screening and throughout trial participation.

11. Agree to not receive immunosuppressive and/or investigational therapies during the study.

Note: Prohibited immunosuppressive medications do not include corticosteroid nasal spray or inhaler; topical corticosteroids for mild, uncomplicated dermatitis; or oral/parenteral corticosteroids given for non-chronic conditions.

12. Has adequate organ function as indicated by the following laboratory values:

* Hematocrit ≥33% or hemoglobin ≥13 g/dL (males) and ≥12 g/dL (females)

* Platelet count ≥150,000/mm3

* Absolute neutrophil count ≥1,500/mm3

* Serum creatinine ≤1.3 times ULN or calculated creatinine clearance (for those with creatinine \>1.3 ULN) ≥60 mL/min

* Prothrombin Time or INR ≤ 1.5 times ULN

* Total bilirubin \<1.5 times the ULN range. If total bilirubin is elevated, direct bilirubin must be \< 2 times the ULN range, except in participants with Gilbert's Syndrome who must have serum bilirubin \<3.0 times ULN (NOTE: If participant is on an atazanavir containing therapy then a direct bilirubin should be measured instead of the total bilirubin and must be ≤ 1.0 mg/dL. Also, asymptomatic elevations due to ART medications are not exclusionary when, in the opinion of the Investigator, the abnormalities are not attributable to intrinsic hepatic disease.

* Amylase \< 3.0 times ULN at the time of screening

* AST (SGOT) and ALT (SGPT): ≤ 3.0 times ULN

What this study is about